Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Biographical Sketch
Matthew Eagleton, MD is a vascular surgeon in the Department of Vascular Surgery of the Sydell and Arnold Miller Family Heart & Vascular Institute at Cleveland Clinic. He is board-certified in vascular and general surgery. Dr. Eagleton’s specialty interests include endovascular and open surgery for complex aortic disease including aortic aneurysms and aortic dissection, aneurysm pathogenesis, pediatric and congenital vascular disease and vessel wall matrix remodeling.
A native of New York, Dr. Eagleton received his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, N.Y., after graduating cum laude with an undergraduate degree. He continued there for his internship and residency training in general surgery, becoming Chief Resident in General Surgery and receiving the Amarendra Sengupta Memorial Prize in Surgery. He became both a Research Fellow and Clinical Fellow in Vascular Surgery at The University of Michigan School of Medicine in Ann Arbor, winning the S. Martin Lindenauer Award for Research and Education. Dr. Eagleton was a Clinical Fellow in Endovascular Surgery at the Cleveland Clinic and appointed as a vascular surgeon from 2002 – 2003. He returned to Cleveland Clinic in 2005 and appointed as a vascular and endovascular surgeon.
Currently, Dr. Eagleton is Associate Professor in the departments of Vascular Surgery and Biomedical Engineering in the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Prior to his 2005 appointment to Cleveland Clinic, he was Assistant Professor in the Department of Surgery at the University of Michigan, Ann Arbor.
Dr. Eagleton’s clinical research has focused primarily on his specialty interests. Currently he is a co-investigator on several studies evaluating the use of branched and fenestrated aortic endografts to treat complex aortic pathology. He is on the editorial board of the Journal of Vascular Surgery and Vascular Disease Managment, and he is an ad hoc reviewer for Circulation and Circulation Research. He has authored or co-authored articles in peer-reviewed journals on his clinical experience and research and co-authored chapters on his specialty interests in medical textbooks. Dr. Eagleton currently receives research support from the National Institutes of Health and the Society for Vascular Surgery Foundation to evaluate the causes and treatments of aortic aneurysms and dissections.
Dr. Eagleton is a Fellow of the American College of Surgeons. He is a Member of the Society of University Surgeons, the Society for Vascular Surgery, the Peripheral Vascular Surgery Society, and the Society for Clinical Vascular Surgery.
Specialty Interests
Aortic aneurysms, thoracic outlet syndrome, aorta surgery, aorta graft, endovascular aorta treatment - thoracic, aortic dissection, endovascular aorta treatment - abdominal, endovascular repair - vascular disease, endovascular repair of abdominal aortic aneurysms, minimally invasive aortic surgery, surgery for thoracic outlet syndrome
Industry Relationships
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 2/15/2010, Dr. Eagleton has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias.
* Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.